Georgia Regents UniversityCancer Center has entered into a master clinical trial agreement with AdvaxisInc., a biotechnology company specializing in cancerimmunotherapies. Under the terms of the agreement, the Cancer Centerwill conduct four clinical trials under the supervision of Cancer CenterDirector Dr. Samir N. Khleif.
The planned trials willfurther develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancerand ADXS-cHER2 for breast cancer.
"The preclinical success we havehad with the Advaxis platform technology has prompted us to move into humantrials with multiple treatment approaches for cervical and breast cancer,"Khleif said. "We hope to see positive results in cervical and breast cancerpatients as we partner with Advaxis in developing its novel treatments."
TheGRU Cancer Center is a multi-disciplinary academic cancer center focused onboth research and clinical treatment. Its patient-centered approach totreatment includes first-in-the-nation treatment protocols, an experimentaltherapeutics program that includes specialized clinics for Phase I trials andimmunotherapy and a variety of ancillary programs – including nutritional andgenetic counseling – designed with holistic healing in mind.
Click here for more information.
1336 Augusta West Parkway
Can't find something?
All content © Copyright 2000 - 2014 Media General Communications Holdings, LLC. A Media General Company.